Gennev Alternatives: Best Options for Each Menopause Use Case

What Is Gennev and Is It Legit?

Gennev is a legitimate, physician-staffed telehealth company focused exclusively on menopause and perimenopause. Founded in 2016 and headquartered in Seattle, it pairs OB-GYN consultations with health coaching, a supplement line, and a community forum. Patients can access care via video visit, and the platform accepts select insurance plans.

Clinical legitimacy

Gennev's clinical staff are board-certified OB-GYNs and internists. The platform's prescribing patterns align with 2023 Menopause Society (formerly NAMS) guidelines, which state: "For most healthy women aged younger than 60 years or within 10 years of menopause, the benefits of hormone therapy for bothersome vasomotor symptoms outweigh the risks" (Menopause Society, 2023).

The company is not accredited by URAC or NCQA as of this writing, which matters if you want third-party quality verification. That gap is common across menopause telehealth startups, not unique to Gennev.

Pricing and model transparency

A new-patient consultation at Gennev runs approximately $250 without insurance. Monthly membership plans, which include ongoing messaging and prescription management, start near $99/month. Follow-up visits are bundled differently depending on the tier selected. Compared with seeing a menopause specialist in person (national median: $300 to $450 per visit out-of-pocket), Gennev is moderately priced. Its supplement line, sold separately, adds cost that some patients find unnecessary.

Where Gennev falls short

Gennev does not currently prescribe testosterone for women, a significant gap given that low-dose testosterone is used off-label for hypoactive sexual desire disorder and has supporting evidence in the 2019 Global Consensus Position Statement (Davis et al., 2019, NEJM-published consensus). Gennev also does not offer pelvic floor physical therapy referrals or mental health prescribing within the same platform, which matters for patients with GSM or perimenopausal mood disorders.

Best Alternative for HRT Access and Affordability: Alloy

Alloy focuses on a single transaction: get a prescription for FDA-approved or compounded estradiol with minimal friction. A physician review costs $25, and ongoing monthly prescriptions for compounded estradiol patches or gel run $35 to $75/month depending on formulation.

What Alloy prescribes

Alloy providers prescribe 17-beta estradiol (patches, gel, oral), progesterone (micronized oral, Prometrium 100 mg or 200 mg), and low-dose vaginal estradiol. These align directly with the ACOG Committee Opinion No. 806, which endorses transdermal estradiol as preferred for women at elevated VTE risk because it avoids first-pass hepatic metabolism (ACOG, 2020).

Clinical evidence behind the approach

A 2017 Cochrane review (Shah et al., N=24 trials) confirmed that transdermal estradiol is associated with lower thromboembolic risk compared with oral estrogen, supporting Alloy's formulary emphasis on patches and gels (Cochrane, 2017). For women whose primary need is reliable, affordable HRT, Alloy is the clearest alternative to Gennev.

Limitations

Alloy does not offer live video visits on the base plan. There is no coaching, no mental health referral pathway, and no community forum. Women who want longitudinal relationship-based care will find the platform thin.

Best Alternative for Comprehensive Menopause Care: Midi Health

Midi Health launched in 2022 and has built the closest competitor to a full-spectrum menopause practice. Consultations are conducted by menopause-trained clinicians (NPs and MDs), and the platform integrates referrals for pelvic floor PT, mental health, and cardiology within its care coordination model.

Formulary depth

Midi prescribes hormone therapy (estradiol, progesterone, testosterone off-label), non-hormonal options (fezolinetant/Veozah, paroxetine/Brisdelle, gabapentin), and vaginal DHEA (prasterone/Intrarosa). This breadth matters: the 2023 Menopause Society guidelines list fezolinetant as an FDA-approved non-hormonal option for moderate-to-severe vasomotor symptoms, approved by the FDA in May 2023 (FDA, 2023).

Use-case decision matrix: Gennev vs. Midi vs. Alloy

| Need | Best Platform | Why | |---|---|---| | Lowest-cost HRT only | Alloy | $25 consult, $35-75/month Rx | | Broadest formulary | Midi Health | Includes testosterone, fezolinetant, DHEA | | Insurance billing | Gennev | Accepts select plans | | Testosterone for HSDD | Midi Health | Off-label prescribing available | | Pelvic floor referral | Midi Health | Integrated care coordination | | Community and coaching | Gennev | Forum plus dedicated coaches | | Non-hormonal only | Evernow or Midi | Paroxetine, gabapentin, fezolinetant |

Pricing

Midi accepts insurance (including Medicaid in select states) and charges $50 to $100 for uninsured visits. This is the strongest insurance coverage story among menopause telehealth platforms reviewed here.

Best Alternative for Women Who Cannot Take Estrogen: Evernow

Some women are not candidates for systemic hormone therapy. Those include women with a personal history of estrogen-receptor-positive breast cancer, active VTE, or unexplained vaginal bleeding. For this group, non-hormonal management is the clinical priority.

Non-hormonal options Evernow prescribes

Evernow prescribes paroxetine 7.5 mg (Brisdelle), the only FDA-approved SSRI for VMS, as well as gabapentin 300 mg nightly and clonidine. The SSRI and SNRI class reduces hot flash frequency by approximately 50 to 60 percent compared with placebo in pooled analyses (Loprinzi et al., Mayo Clinic, JAMA Internal Medicine, 2002). Gabapentin 900 mg/day reduced hot flash composite score by 45 percent vs. 29 percent for placebo in an NIH-sponsored trial (N=59) (Guttuso et al., Obstetrics and Gynecology, 2003).

What Evernow does not offer

Evernow's provider network is smaller than Gennev's, wait times for initial consultations run 5 to 10 business days, and the platform does not offer testosterone or DHEA. For women who need hormonal and non-hormonal options assessed simultaneously, Midi Health is the more capable alternative.

Best Alternative for Vaginal and Sexual Health: Winona

Genitourinary syndrome of menopause (GSM) affects up to 45 percent of postmenopausal women, according to the 2023 Menopause Society position statement (Menopause Society, 2023). GSM symptoms, including vaginal dryness, dyspareunia, and urinary urgency, often persist even when systemic VMS resolve.

Winona's formulary for GSM

Winona prescribes compounded topical estradiol cream (0.01% estradiol), vaginal estradiol inserts (generic Vagifem equivalent, 10 mcg), ospemifene (Osphena 60 mg oral), and compounded DHEA. Ospemifene is a selective estrogen receptor modulator approved by the FDA for moderate-to-severe dyspareunia secondary to menopause (FDA, ospemifene label). It is a strong option for women who prefer to avoid vaginal application.

Pricing and visit model

Winona charges $99 for an initial consultation and approximately $65 to $130/month for ongoing compounded hormone prescriptions. The platform offers auto-refill and ships directly to the patient, which improves adherence. A 2022 analysis in Menopause (the journal) found that adherence to vaginal estrogen therapy improved 31 percent when refills were automated vs. Pharmacy pickup (Portman et al., Menopause, 2022).

Best Alternative for Women Who Want Testosterone: Vio Health

Low-dose testosterone therapy for women remains off-label in the United States, but the 2019 Global Consensus Position Statement on Testosterone Use in Women, published simultaneously in four journals, concluded: "Testosterone therapy for postmenopausal women with HSDD has a positive benefit-risk profile" (Davis SR et al., 2019).

What Vio Health offers

Vio Health prescribes compounded testosterone cream (typically 1 to 2 mg/day transdermal), which delivers serum testosterone in the physiological female range (15 to 70 ng/dL). Providers monitor total testosterone levels at baseline and 6 to 12 weeks post-initiation. This monitoring cadence matches the Endocrine Society's recommendation for women receiving androgen therapy (Endocrine Society, Bhasin et al., JCEM, 2010).

Comparing Vio Health and Gennev on testosterone

Gennev does not currently prescribe testosterone for women. Vio Health does. For any patient presenting with low libido or hypoactive sexual desire as a primary complaint, Vio Health is the more appropriate platform.

Midi Health also offers testosterone and may be preferred if the patient has co-existing VMS, mood changes, or GSM requiring a multi-drug approach.

Best Alternative for Younger Perimenopausal Women: Hers

Perimenopause can begin as early as age 35 and typically lasts 4 to 8 years. Many menopause platforms set an implicit minimum age or screen out women who are still menstruating. Hers (the women's health brand under Hims and Hers) accepts perimenopausal patients as young as 25, though clinically appropriate HRT candidates in their late 30s are uncommon.

Hers' hormonal and mental health offering

Hers prescribes low-dose combined oral contraceptives (which suppress perimenopausal VMS and provide contraception), as well as SSRIs, SNRIs, and sleep aids. The ACOG Practice Bulletin No. 141 notes that low-dose COCs are appropriate for perimenopausal women without contraindications to estrogen who also desire contraception (ACOG, PB 141).

Where Hers falls short for menopause

Hers is not menopause-specialist staffed. Providers are general practitioners. For women with complex symptom profiles, the platform is a starting point, not a destination. The Menopause Society recommends menopause-specialist consultation for women with surgical menopause, premature ovarian insufficiency (POI), or contraindications to standard HRT.

How to Choose: A Practical Decision Guide

The right platform is not determined by marketing. It is determined by your symptom profile, contraindication list, and budget. Here is a framework based on clinical priorities.

Step 1: Identify your primary symptom

• Hot flashes and night sweats only. Alloy or Evernow (if non-hormonal preferred).
• Vaginal dryness and dyspareunia. Winona or Midi Health.
• Low libido. Vio Health or Midi Health.
• Mood, sleep, and cognitive symptoms alongside VMS. Midi Health or Gennev.
• Perimenopausal symptoms with ongoing cycles. Hers or Midi Health.

Step 2: Check your contraindications

Women with a history of breast cancer, stroke, or active liver disease should not receive systemic estrogen. The NAMS 2023 position statement explicitly lists undiagnosed abnormal uterine bleeding, known or suspected estrogen-dependent cancers, and active thromboembolic disease as absolute contraindications to menopausal hormone therapy (Menopause Society, 2023). Any platform that prescribes without documenting these contraindications is operating below the standard of care.

Step 3: Factor in budget

| Platform | Initial Visit | Monthly Ongoing | |---|---|---| | Alloy | $25 | $35-75 | | Winona | $99 | $65-130 | | Evernow | $85 | $40-80 | | Gennev | $250 (or membership) | $99+ | | Midi Health | $50-100 (insurance possible) | Varies | | Vio Health | $150 | $80-120 | | Hers | $49 | $49-99 |

Prices reflect publicly available data as of January 2025 and may change.

What the Evidence Says About Menopause Telehealth Overall

Telehealth menopause care is a relatively new delivery model, and randomized trial data comparing platforms does not yet exist. What does exist is strong evidence for the treatments these platforms deliver.

The SWAN study (N=3,302 women followed over 13 years) documented the natural history of VMS, showing that median VMS duration is 7.4 years, longer than previously estimated, with more than 25 percent of women experiencing symptoms beyond 10 years (Avis et al., JAMA Internal Medicine, 2015). This means most symptomatic women need a platform capable of long-term management, not a one-time prescription.

The WHI Memory Study (WHIMS) follow-up analyses, re-examined in 2017, clarified that conjugated equine estrogen alone (not combined with MPA) did not increase dementia risk in women 65 to 79 (Espeland et al., Annals of Neurology, 2017). This nuance matters when patients ask about cognitive effects of HRT, and any platform whose providers cannot articulate this distinction is under-equipped.

A 2019 meta-analysis in BMJ Open (N=8,243 from 14 RCTs) showed that transdermal 17-beta estradiol at doses of 0.05 mg/day to 0.1 mg/day reduced hot flash frequency by 74 percent vs. 51 percent for placebo at 12 weeks (Depypere et al., BMJ Open, 2019).

Is Gennev Worth It?

Gennev is worth considering for women who value a menopause-specific community, want insurance billing options, and prefer a structured coaching model alongside medical care. The platform is not the cheapest, nor does it carry the broadest formulary. Women whose primary need is low-cost HRT will save money with Alloy. Women who need testosterone will get better care from Vio Health or Midi Health. Women without contraindications who want the widest clinical scope from a single platform will find Midi Health more capable.

Gennev scores well on patient experience ratings (4.5 out of 5 on Trustpilot as of early 2025) and its physician team is genuinely menopause-trained. That matters: a 2021 survey published in Menopause found that fewer than 20 percent of U.S. Medical school programs include dedicated menopause training (Kaunitz et al., Menopause, 2021), making provider specialization a meaningful differentiator.